Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- PeptiDream, 4 Other Firms Establish JV to Develop COVID-19 Therapeutics
November 13, 2020
- Ex-Daiichi Sankyo Chairman Kiyoshi Morita Dies at 81
November 13, 2020
- Fujifilm Grants Rights to Patent on iPS Cell Generation to Lonza
November 13, 2020
- Taiho Obtains Japan Rights for US Firm’s Loculated Pleural Effusion Med
November 13, 2020
- AstraZeneca Launches Healthcare Innovation Hub in Japan
November 12, 2020
- Nippon Kayaku’s Biosimilar Sales to Hit 10 Billion Yen Mark in Full-Year, Trastuzumab Upbeat
November 12, 2020
- Roche Diagnostics Rolls Out COVID-19 Antibody Detection Reagent in Japan for Research Use
November 12, 2020
- New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
November 12, 2020
- Medicago’s COVID-19 Vaccine Shows Positive PI Results, Now Gearing Up for PII, PIII Studies
November 12, 2020
- Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
- Lenvima Plus Keytruda Yield Positive Data in 1st Line RCC
November 11, 2020
- AnGes to Buy US Gene Editing Therapeutics Firm Emendo
November 10, 2020
- Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers
November 10, 2020
- Ono/BMS Sign Patent License Deal for Tecentriq with Roche
November 10, 2020
- Japan Ethical Drug Sales Drop 9.6% in September: Crecon
November 10, 2020
- Ono Launches Japan PIII Study for Foipan for COVID-19
November 10, 2020
- Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
- Kyorin Jettisons Gene Therapy Ad-SGE-REIC after Bleak PII Results
November 9, 2020
- Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
- Xtandi Approved in China for Non-Metastatic CRPC
November 9, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…